Eli Lilly Launched Direct-to-Consumer Mounjaro Delivery
Patients can now access the diabetes and obesity treatment through an online platform.
Updated on Sept. 30, 2026 in Diabetes
Live Poll
Do you trust pharmaceutical companies to handle direct-to-consumer delivery of prescription medication?
Eli Lilly has expanded its LillyDirect platform to Australia to facilitate the home delivery of Mounjaro. The service allows patients with a doctor-issued e-script to receive the medication through a third-party pharmacy.
Why it matters
The company launched the platform to increase drug convenience and affordability for users managing type 2 diabetes and obesity. It arrives as patients navigate significant out-of-pocket costs for the medication.
LillyDirect enables home delivery for patients with a valid e-script, potentially reducing monthly costs by up to $50 from a peak of $700. The platform's efficacy as a distribution model remains under investigation by medical professionals.
The players
Eli Lilly
A pharmaceutical company that researches and manufactures diabetes and weight management therapies like Mounjaro.
The details
Mounjaro is an injectable GLP-1 agonist designed to regulate blood glucose levels in patients with type 2 diabetes and manage weight in those with obesity. Through LillyDirect, patients submit an electronic script to a third-party pharmacist who then coordinates home fulfillment. This shift in the supply chain bypasses traditional retail interactions, a change that has drawn criticism from doctors and pharmacists regarding current prescribing standards.
Timeline
LillyDirect launched in the United States in 2024.
Eli Lilly declined a Pharmaceutical Benefits Scheme listing in April 2026.
LillyDirect launched in Australia in September 2026.
Health Landscape
The introduction of direct-to-consumer platforms marks a departure from traditional pharmacy distribution models for specialty chronic disease medications. This development follows Eli Lilly's decision to forgo listing Mounjaro on the Pharmaceutical Benefits Scheme, influencing how patients access the drug.
Patients should discuss whether home-delivered medication is appropriate for their specific treatment plan with their primary physician. It is also important to note that government regulations now require prescribers to record all medicine-related information in official systems.
The takeaway
Direct-to-consumer platforms for chronic medications offer convenience but change the typical relationship between patients, doctors, and pharmacists. Always confirm with your physician how new delivery models might affect the documentation and tracking of your ongoing medical prescriptions.
Further reading
Learn more about managing your care by visiting our Diabetes section.
Source note: This article includes information reported by Australian Broadcasting Corporation.
Live Poll
Do you trust pharmaceutical companies to handle direct-to-consumer delivery of prescription medication?
